


From: [REDACTED]
Sent: Wed Jun 28 2006 15:37:27 EDT
To: [REDACTED]
CC: [REDACTED];cara
lansden/cambridge/biogen@biogenidec;gilmore o'neill/cambridge/biogen@biogenidec; [REDACTED]
Subject: BG-12 Country Selection Information - Friday Mtg.

To support our Friday meeting (10 AM Cambridge, 4 PM Zug) to discuss Country selection for the BG-12 Phase III trials, Clinical has kindly assembled the attached document. The file contains the following information:

The first tab is a summary showing the countries, # investigators we've worked with or contacted for previous studies, and # new potential investigators that our feasibility CRO were able to get to respond to the questionnaire. Most importantly, the comments section provides rationale for the Clinical recommendation to use the country (or not).
The second tab shows the investigators (both new and previously contacted by us) who were used in our assessment, in case there is a question.



I would appreciate it if you could take a look prior to the Friday meeting and come prepared with questions and hopefully recommendations.

[REDACTED]
New Product Commercialization
Biogen Idec